Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved..
BACKGROUND & AIMS: Recently, a group of hepatologists proposed to rename non-alcoholic fatty liver disease (NAFLD) as metabolic associated fatty liver disease (MAFLD) with modified diagnostic criteria. We aimed to study the impact of the new definition on the epidemiology of fatty liver disease.
METHODS: We randomly selected 1013 adults from the Hong Kong census database for clinical assessment, proton-magnetic resonance spectroscopy, and transient elastography. Five hundred sixty-five subjects without fatty liver at baseline underwent follow-up assessment. MAFLD was diagnosed as intrahepatic triglyceride content (IHTG) ≥5% and the presence of overweight/obesity, diabetes, or two other metabolic risk factors, with and without concomitant liver diseases. The diagnosis of NAFLD required the exclusion of concomitant liver diseases; metabolic factors were not considered.
RESULTS: The population prevalence of MAFLD and NAFLD was 25.9% (95% CI 23.2-28.7%) and 25.7% (95% CI 23.1-28.5%), respectively. Among 277 subjects with IHTG ≥5%, 247 (89.2%) fulfilled both the definitions of MAFLD and NAFLD. Fourteen subjects (5.1%) had IHTG ≥5% but did not meet the metabolic criteria of MAFLD. The incidence of MAFLD was 2.8 per 100 person-years at a median interval of 47 months (range 34-60 months). Among 78 subjects with incident NAFLD, 59 (75.6%) met the criteria of MAFLD; only one of the latter, a regular drinker, had liver stiffness ≥10 kPa.
CONCLUSIONS: The new definition of MAFLD does not significantly change the prevalence compared with NAFLD, but it may reduce the incidence by 25%. People with hepatic steatosis but not fulfilling the definition of MAFLD unlikely have significant liver disease.
| Errataetall: |
CommentIn: Clin Gastroenterol Hepatol. 2021 Dec;19(12):2683-2684. - PMID 33581358 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 19(2021), 10 vom: 01. Okt., Seite 2161-2171.e5 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wong, Vincent Wai-Sun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 04.10.2021 Date Revised 02.06.2022 published: Print-Electronic CommentIn: Clin Gastroenterol Hepatol. 2021 Dec;19(12):2683-2684. - PMID 33581358 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cgh.2020.10.046 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317058231 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317058231 | ||
| 003 | DE-627 | ||
| 005 | 20231225162431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cgh.2020.10.046 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM317058231 | ||
| 035 | |a (NLM)33137486 | ||
| 035 | |a (PII)S1542-3565(20)31504-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wong, Vincent Wai-Sun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2021 | ||
| 500 | |a Date Revised 02.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin Gastroenterol Hepatol. 2021 Dec;19(12):2683-2684. - PMID 33581358 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND & AIMS: Recently, a group of hepatologists proposed to rename non-alcoholic fatty liver disease (NAFLD) as metabolic associated fatty liver disease (MAFLD) with modified diagnostic criteria. We aimed to study the impact of the new definition on the epidemiology of fatty liver disease | ||
| 520 | |a METHODS: We randomly selected 1013 adults from the Hong Kong census database for clinical assessment, proton-magnetic resonance spectroscopy, and transient elastography. Five hundred sixty-five subjects without fatty liver at baseline underwent follow-up assessment. MAFLD was diagnosed as intrahepatic triglyceride content (IHTG) ≥5% and the presence of overweight/obesity, diabetes, or two other metabolic risk factors, with and without concomitant liver diseases. The diagnosis of NAFLD required the exclusion of concomitant liver diseases; metabolic factors were not considered | ||
| 520 | |a RESULTS: The population prevalence of MAFLD and NAFLD was 25.9% (95% CI 23.2-28.7%) and 25.7% (95% CI 23.1-28.5%), respectively. Among 277 subjects with IHTG ≥5%, 247 (89.2%) fulfilled both the definitions of MAFLD and NAFLD. Fourteen subjects (5.1%) had IHTG ≥5% but did not meet the metabolic criteria of MAFLD. The incidence of MAFLD was 2.8 per 100 person-years at a median interval of 47 months (range 34-60 months). Among 78 subjects with incident NAFLD, 59 (75.6%) met the criteria of MAFLD; only one of the latter, a regular drinker, had liver stiffness ≥10 kPa | ||
| 520 | |a CONCLUSIONS: The new definition of MAFLD does not significantly change the prevalence compared with NAFLD, but it may reduce the incidence by 25%. People with hepatic steatosis but not fulfilling the definition of MAFLD unlikely have significant liver disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Magnetic Resonance Spectroscopy | |
| 650 | 4 | |a Metabolic Syndrome | |
| 650 | 4 | |a Nonalcoholic Fatty Liver Disease | |
| 650 | 4 | |a Nonalcoholic Steatohepatitis | |
| 650 | 4 | |a Transient Elastography | |
| 700 | 1 | |a Wong, Grace Lai-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Woo, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Abrigo, Jill M |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Carmen Ka-Man |e verfasserin |4 aut | |
| 700 | 1 | |a Shu, Sally She-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Leung, Julie Ka-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Chim, Angel Mei-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Alice Pik-Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Lui, Grace Chung-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Henry Lik-Yuen |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Winnie Chiu-Wing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association |d 2003 |g 19(2021), 10 vom: 01. Okt., Seite 2161-2171.e5 |w (DE-627)NLM147178851 |x 1542-7714 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2021 |g number:10 |g day:01 |g month:10 |g pages:2161-2171.e5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cgh.2020.10.046 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2021 |e 10 |b 01 |c 10 |h 2161-2171.e5 | ||